The adverse impact of COVID-19 pandemic on cardiovascular disease prevention and management in England, Scotland and Wales: A population-scale analysis of trends in medication data

Caroline E Dale, Rohan Takhar, Ray Carragher, Fatemeh Torabi, Michalis Katsoulis, Stephen Duffield, Seamus Kent, Tanja Mueller, Amanj Kurdi, Stuart McTaggart, Hoda Abbasizanjani, Sam Hollings, Andrew Scourfield, Ronan Lyons, Rowena Griffiths, Jane Lyons, Gareth Davies, Dan Harris, Alex Handy, Mehrdad Alizadeh Mizani, Chris Tomlinson, Mark Ashworth, Spiros Denaxas, Amitava Banerjee, Jonathan Sterne, Kate Lovibond, Paul Brown, Ian Bullard, Rouven Priedon, Mamas A Mamas, Ann Slee, Paula Lorgelly, Munir Pirmohamed, Kamlesh Khunti, Naveed Sattar, Andrew Morris, Cathie Sudlow, Ashley Akbari, Marion Bennie, Reecha Sofat on behalf of the CVD-COVID-UK Consortium
doi: https://doi.org/10.1101/2021.12.31.21268587

Article Information

doi 
https://doi.org/10.1101/2021.12.31.21268587
History 
  • January 7, 2022.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Caroline E Dale1,*,
  2. Rohan Takhar1,*,
  3. Ray Carragher2,
  4. Fatemeh Torabi3,
  5. Michalis Katsoulis1,
  6. Stephen Duffield4,
  7. Seamus Kent4,
  8. Tanja Mueller5,
  9. Amanj Kurdi2,
  10. Stuart McTaggart6,
  11. Hoda Abbasizanjani3,
  12. Sam Hollings7,
  13. Andrew Scourfield8,
  14. Ronan Lyons3,
  15. Rowena Griffiths3,
  16. Jane Lyons3,
  17. Gareth Davies3,
  18. Dan Harris3,
  19. Alex Handy1,
  20. Mehrdad Alizadeh Mizani1,
  21. Chris Tomlinson1,
  22. Mark Ashworth9,
  23. Spiros Denaxas1,
  24. Amitava Banerjee1,
  25. Jonathan Sterne10,
  26. Kate Lovibond11,
  27. Paul Brown7,
  28. Ian Bullard7,
  29. Rouven Priedon12,
  30. Mamas A Mamas13,
  31. Ann Slee14,
  32. Paula Lorgelly15,
  33. Munir Pirmohamed16,
  34. Kamlesh Khunti17,
  35. Naveed Sattar18,
  36. Andrew Morris19,
  37. Cathie Sudlow12,
  38. Ashley Akbari3,
  39. Marion Bennie5,
  40. Reecha Sofat1,16,* and
  41. on behalf of the CVD-COVID-UK Consortium
  1. 1Institute of Health Informatics Research, University College London
  2. 2Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde
  3. 3Swansea University
  4. 4The National Institute for Health and Care Excellence
  5. 5University of Strathclyde
  6. 6Public Health Scotland
  7. 7NHS Digital, Leeds
  8. 8UCLH NHS Foundation Trust
  9. 9King’s College London
  10. 10University of Bristol
  11. 11Royal College of Physicians
  12. 12British Heart Foundation Data Science Centre, Health Data Research UK, London
  13. 13Keele University
  14. 14NHSX
  15. 15Department of Applied Health Research, University College London
  16. 16University of Liverpool
  17. 17University of Leicester
  18. 18University of Glasgow
  19. 19Health Data Research UK
  1. ↵*Corresponding author; email: r.sofat{at}ucl.ac.uk
Back to top
Posted January 07, 2022.
Download PDF
Data/Code
Email
The adverse impact of COVID-19 pandemic on cardiovascular disease prevention and management in England, Scotland and Wales: A population-scale analysis of trends in medication data
Caroline E Dale, Rohan Takhar, Ray Carragher, Fatemeh Torabi, Michalis Katsoulis, Stephen Duffield, Seamus Kent, Tanja Mueller, Amanj Kurdi, Stuart McTaggart, Hoda Abbasizanjani, Sam Hollings, Andrew Scourfield, Ronan Lyons, Rowena Griffiths, Jane Lyons, Gareth Davies, Dan Harris, Alex Handy, Mehrdad Alizadeh Mizani, Chris Tomlinson, Mark Ashworth, Spiros Denaxas, Amitava Banerjee, Jonathan Sterne, Kate Lovibond, Paul Brown, Ian Bullard, Rouven Priedon, Mamas A Mamas, Ann Slee, Paula Lorgelly, Munir Pirmohamed, Kamlesh Khunti, Naveed Sattar, Andrew Morris, Cathie Sudlow, Ashley Akbari, Marion Bennie, Reecha Sofat
medRxiv 2021.12.31.21268587; doi: https://doi.org/10.1101/2021.12.31.21268587
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area